Low μ-Opioid Receptor Status in Alcohol Dependence Identified by Combined Positron Emission Tomography and Post-Mortem Brain Analysis.
- Authors
- Hermann, Derik; Hirth, Natalie; Reimold, Matthias; Batra, Anil; Smolka, Michael N; Hoffmann, Sabine; Kiefer, Falk; Noori, Hamid R; Sommer, Wolfgang H; Reischl, Gerald; la Fougère, Christian; Mann, Karl; Spanagel, Rainer; Hansson, Anita C
- Year
- 2017
- Journal
- Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
- PMID
- 27510425
- DOI
- 10.1038/npp.2016.145
- PMCID
- PMC5240173
Blockade of the μ-opioid receptor (MOR) by naltrexone reduces relapse risk in a subpopulation of alcohol-dependent patients. Previous positron-emission-tomography (PET) studies using the MOR ligand [C]carfentanil have found increased MOR availability in abstinent alcoholics, which may reflect either increased MOR expression or lower endogenous ligand concentration. To differentiate between both effects, we investigated two cohorts of alcoholic subjects using either post-mortem or clinical PET analysis. Post-mortem brain tissue of alcohol-dependent subjects and controls (N=43/group) was quantitatively analyzed for MOR ([H]DAMGO)-binding sites and OPRM1 mRNA in striatal regions. [C]carfentanil PET was performed in detoxified, medication free alcohol-dependent patients (N=38), followed by a randomized controlled study of naltrexone versus placebo and follow-up for 1 year (clinical trial number: NCT00317031). Because the functional OPRM1 variant rs1799971:A>G affects the ligand binding, allele carrier status was considered in the analyses. MOR-binding sites were reduced by 23-51% in post-mortem striatal tissue of alcoholics. In the PET study, a significant interaction of OPRM1 genotype, binding potential (BP) for [C]carfentanil in the ventral striatum, and relapse risk was found. Particularly in G-allele carriers, lower striatal BP was associated with a higher relapse risk. Interestingly, this effect was more pronounced in the naltrexone treatment group. Reduced MOR is interpreted as a neuroadaptation to an alcohol-induced release of endogenous ligands in patients with severe alcoholism. Low MOR availability may explain the ineffectiveness of naltrexone treatment in this subpopulation. Finally, low MOR-binding sites are proposed as a molecular marker for a negative disease course.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Analysis of whole genome-transcriptomic organization in brain to identify genes associated with alcoholism. | 2019 | 30765688 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Methodological considerations for interpreting ketamine-naltrexone trials in depression. | Bandeira ID et al. | — | 2025 | → |
| Molecular Imaging Studies of Alcohol Use Disorder. | Bach P et al. | — | 2025 | → |
| Opioid Regulation of Social Homeostasis: Connecting Loneliness to Addiction. | Løseth G et al. | — | 2025 | → |
| Precision medicine in substance use disorders: Integrating behavioral, environmental, and biological insights. | Guerrin CGJ et al. | — | 2025 | → |
| The Dopamine System in Mediating Alcohol Effects in Humans. | Beck A et al. | — | 2025 | → |
| The Neuropathology of Alcohol Use Disorder: Cellular Insights From Human Post-Mortem Studies. | Rasool AE et al. | — | 2025 | → |
| Validation of <i>GDAP1</i> and <i>HECW2</i> as Epigenetic Markers of Alcohol Use Disorder in Blood and Brain. | Wiegand A et al. | — | 2025 | → |
| Cholinergic mu-opioid receptor deletion alters reward preference and aversion-resistance. | Beane CR et al. | — | 2024 | → |
| Endogenous mu-opioid modulation of social connection in humans: a systematic review and meta-analysis. | Løseth G et al. | — | 2024 | → |
| Neurocircuitry underlying the actions of glucagon-like peptide 1 and peptide YY<sub>3</sub><sub>-</sub><sub>36</sub> in the suppression of food, drug-seeking, and anxiogenesis. | Dumiaty Y et al. | — | 2024 | → |
| The influence of drug class on reward in substance use disorders. | Jones JD et al. | — | 2024 | → |
| The Roles of Endogenous D2R Dopamine and μ-opioid Receptors of the Brain in Alcohol use Disorder. | Khikhmetova K et al. | — | 2024 | → |
| β-Endorphin influences sedative and ataxic effects of alcohol. | Stea SG et al. | — | 2024 | → |
| Cholinergic mu-opioid receptor deletion alters reward preference and aversion-resistance | Beane CR et al. | — | 2023 | — |
| Stress-related neuropeptide systems as targets for treatment of alcohol addiction: A clinical perspective. | Heilig M | — | 2023 | → |
| Disrupted circadian expression of β-arrestin 2 affects reward-related µ-opioid receptor function in alcohol dependence. | Meinhardt MW et al. | — | 2022 | → |
| Hazardous drinking and alcohol use disorders. | MacKillop J et al. | — | 2022 | → |
| Risk for opioid misuse in chronic pain patients is associated with endogenous opioid system dysregulation. | Ballester J et al. | — | 2022 | → |
| Alcohol and the Brain. | Nutt D et al. | — | 2021 | → |
| Dysregulation of the histone demethylase KDM6B in alcohol dependence is associated with epigenetic regulation of inflammatory signaling pathways. | Johnstone AL et al. | — | 2021 | → |
| Early Life Stress and Risks for Opioid Misuse: Review of Data Supporting Neurobiological Underpinnings. | Oswald LM et al. | — | 2021 | → |
| Targeting the Opioid Receptors: A Promising Therapeutic Avenue for Treatment in "Heavy Drinking Smokers". | Domi A et al. | — | 2021 | → |
| Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals. | Turton S et al. | — | 2020 | → |
| Endogenous opiates and behavior: 2017. | Bodnar RJ | — | 2020 | → |
| Neuroendocrine effects of naltrexone versus nalmefene in humans. | Butelman ER et al. | — | 2020 | → |
| Nicotine increases alcohol self-administration in male rats via a μ-opioid mechanism within the mesolimbic pathway. | Domi E et al. | — | 2020 | → |
| Alcohol Interaction with Cocaine, Methamphetamine, Opioids, Nicotine, Cannabis, and γ-Hydroxybutyric Acid. | Singh AK | — | 2019 | → |
| Analysis of whole genome-transcriptomic organization in brain to identify genes associated with alcoholism. | Kapoor M et al. | — | 2019 | → |
| A Survey of Molecular Imaging of Opioid Receptors. | Cumming P et al. | — | 2019 | → |
| Developing neuroscience-based treatments for alcohol addiction: A matter of choice? | Heilig M et al. | — | 2019 | → |
| Dopamine and opioid systems adaptation in alcoholism revisited: Convergent evidence from positron emission tomography and postmortem studies. | Hansson AC et al. | — | 2019 | → |
| Ethanol activates immune response in lymphoblastoid cells. | McClintick JN et al. | — | 2019 | → |
| History of Alcohol and Opioid Use Impacts on the Long-Term Recovery Trajectories of Methamphetamine-Dependent Patients. | Tan H et al. | — | 2019 | → |
| Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging? | Colom M et al. | — | 2019 | → |
| Neuroimaging of reward mechanisms in Gambling disorder: an integrative review. | Clark L et al. | — | 2019 | → |
| Positron Emission Tomography: Updates on Imaging of Addiction. | Solingapuram Sai JKK et al. | — | 2019 | → |
| Reduced mu opioid receptor availability in schizophrenia revealed with [<sup>11</sup>C]-carfentanil positron emission tomographic Imaging. | Ashok AH et al. | — | 2019 | → |
| The selective κ-opioid receptor antagonist JDTic attenuates the alcohol deprivation effect in rats. | Uhari-Väänänen J et al. | — | 2019 | → |
| Defining Substance Use Disorders: The Need for Peripheral Biomarkers. | Bough KJ et al. | — | 2018 | → |
| Dynorphin and κ-Opioid Receptor Dysregulation in the Dopaminergic Reward System of Human Alcoholics. | Bazov I et al. | — | 2018 | → |
| Focusing on the Opioid System for Addiction Biomarker Discovery. | Belzeaux R et al. | — | 2018 | → |
| Opioid receptors: drivers to addiction? | Darcq E et al. | — | 2018 | → |
| Oxytocin Reduces Alcohol Cue-Reactivity in Alcohol-Dependent Rats and Humans. | Hansson AC et al. | — | 2018 | → |
| The κ-opioid receptor antagonist JDTic decreases ethanol intake in alcohol-preferring AA rats. | Uhari-Väänänen J et al. | — | 2018 | → |
| Pharmacotherapy of alcoholism - an update on approved and off-label medications. | Soyka M et al. | — | 2017 | → |